Jennifer Chang joined Immatics in April 2026 and is responsible for leading the launch strategy, planning and execution of its first anticipated commercial product, Anzu-cel (IMA-203). Her scope includes driving pre-launch readiness across key functions and launch activities with strategic alignment and operational excellence.
She brings more than 20 years of experience in the biopharmaceutical industry across commercialization and launch leadership, with deep experience in oncology and cell therapy. Jennifer has spent her career advancing healthcare through commercialization of innovative therapies and by building and leading high performing teams. Prior to joining Immatics, she held roles at Biogen, Gen Probe, GlaxoSmithKline, Amgen, PwC Health Industries Advisory and Iovance Biotherapeutics.
Jennifer Chang holds an MBA from UCLA Anderson School of Management, an MPH from USC Keck School of Medicine and a B.S. in Biochemistry/Cell Biology from UCSD.